Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Eisai
Eisai
European Commission Approves New First Line Treatment for Advanced or Unresectable Hepatocellular Carcinoma – First in a Decade
Thu, 08/23/18 - 10:09 am
Eisai
Merck
Lenvima
hepatocellular carcinoma
Eisai-Merck partnership picks up first-line Lenvima approval
Biopharma Dive
Tue, 08/21/18 - 10:16 am
FDA
Eisai
Merck
Lenvima
hepatocellular carcinoma
Japan's Eisai sets price tag of about $16,000 on liver cancer drug
Yahoo/Reuters
Thu, 08/16/18 - 11:12 pm
Eisai
liver cancer
drug pricing
Lenvima
Why Biogen's Stock Ripped Higher in July
Motley Fool
Mon, 08/13/18 - 09:41 am
Biogen
Eisai
BAN2401
Alzheimer's disease
Spinraza
Ionis Pharmaceuticals
Biogen’s high-stakes Alzheimer’s gamble is being roasted by the experts. Is the amyloid beta theory dead?
Endpoints
Thu, 08/9/18 - 09:16 am
Biogen
Eisai
BAN2401
Alzheimer's disease
FOCUS-Eisai/Biogen to advance Alzheimer's drug, provide fresh hope
Yahoo/Reuters
Sun, 08/5/18 - 12:22 pm
Biogen
Eisai
Alzheimer's disease
BAN2401
Eisai's Lenvima posts big growth numbers as Merck collaboration rolls into action
Fierce Pharma
Fri, 08/3/18 - 11:33 am
Merck
Eisai
Lenvima
kidney cancer
thyroid cancer
Why the Latest Alzheimer’s Drug Study Has So Many People Confused
Fortune
Mon, 07/30/18 - 11:55 pm
Biogen
Eisai
BAN2401
clinical trials
Alzheimer's disease
Eisai, Biogen outline a 30% and 47% advantage for their Alzheimer’s drug BAN2401 — but critics drag stock down
Endpoints
Wed, 07/25/18 - 05:11 pm
Biogen
Eisai
Alzheimer's disease
BAN2401
clinical trials
As Eisai, Biogen plot a course to accelerated approvals for Alzheimer’s drug, a mob of skeptics are waiting to decipher hard numbers
Endpoints
Tue, 07/24/18 - 11:30 am
Eisai
Biogen
Alzheimer's disease
BAN2401
AAIC
Eisai obesity drug Belviq may have an edge with new heart safety data—but to what end?
Fierce Pharma
Wed, 07/18/18 - 10:56 am
Eisai
obesity
Belviq
AAIC event – Biogen and Eisai move to consolidate beta-amyloid lead
EP Vantage
Tue, 07/17/18 - 11:20 pm
Biogen
Eisai
BAN2401
Alzheimer's disease
Gilead’s Kite taps Eisai cancer vet Amoroso to lead the charge for CAR-T sales
Fierce Pharma
Tue, 07/10/18 - 11:29 am
Gilead Sciences
CAR-T
Eisai
The Biogen Bump Bodes Well for Biotech
Barron's
Sat, 07/7/18 - 04:32 pm
Biogen
Eisai
Alzheimer's disease
BAN2401
Eisai is building a bespoke Cambridge research center with a $100M-plus plan to find new ways to tackle Alzheimer’s
Endpoints
Wed, 06/13/18 - 09:37 am
Eisai
R&D
Cambridge MA
Alzheimer's disease
Eisai, Purdue reveal eye-opening data for sleep drug lemborexant
Fierce Biotech
Wed, 06/6/18 - 09:38 am
Eisai
Purdue Pharma
lemborexant
sleep disorders
clinical trials
insomnia
ASCO: Merck and its new multibillion-dollar partners hone plans for marketing onslaught
Fierce Pharma
Mon, 06/4/18 - 12:09 pm
Merck
ASCO 2018
Keytruda
AstraZeneca
Eisai
FDA stalls Eisai—and its new partner Merck—in quest to widen cancer med Lenvima's reach
Fierce Pharma
Fri, 05/25/18 - 12:15 pm
Merck
Eisai
Lenvima
liver cancer
FDA
Eisai Submits Supplemental New Drug Application (sNDA) to FDA for FYCOMPA (perampanel) Pediatric Indications
CP Wire
Mon, 04/2/18 - 03:03 pm
Eisai
FDA
Fycompa
pediatric
seizures
Eisai Submits Supplemental New Drug Application (sNDA) to FDA for FYCOMPA (perampanel) Pediatric Indications
Mon, 04/2/18 - 12:31 am
Fycompa
Eisai
pediatric epilepsy
Pages
« first
‹ previous
…
5
6
7
8
9
10
11
12
13
…
next ›
last »